- Home
- DSP vs NMRA Comparison
DSP vs NMRA Comparison
Compare DSP & NMRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DSP
- NMRA
- Stock Information
- Founded
- DSP 1999
- NMRA 2019
- Country
- DSP United States
- NMRA United States
- Employees
- DSP N/A
- NMRA N/A
- Industry
- DSP EDP Services
- NMRA
- Sector
- DSP Technology
- NMRA
- Exchange
- DSP Nasdaq
- NMRA Nasdaq
- Market Cap
- DSP 220.3M
- NMRA 121.0M
- IPO Year
- DSP 2021
- NMRA 2023
- Fundamental
- Price
- DSP $13.78
- NMRA $0.84
- Analyst Decision
- DSP Strong Buy
- NMRA Buy
- Analyst Count
- DSP 8
- NMRA 8
- Target Price
- DSP $21.75
- NMRA $9.29
- AVG Volume (30 Days)
- DSP 242.9K
- NMRA 1.4M
- Earning Date
- DSP 08-11-2025
- NMRA 08-05-2025
- Dividend Yield
- DSP N/A
- NMRA N/A
- EPS Growth
- DSP N/A
- NMRA N/A
- EPS
- DSP 0.13
- NMRA N/A
- Revenue
- DSP $306,484,000.00
- NMRA N/A
- Revenue This Year
- DSP $18.36
- NMRA N/A
- Revenue Next Year
- DSP $15.95
- NMRA N/A
- P/E Ratio
- DSP $106.28
- NMRA N/A
- Revenue Growth
- DSP 30.64
- NMRA N/A
- 52 Week Low
- DSP $8.70
- NMRA $0.61
- 52 Week High
- DSP $26.33
- NMRA $17.19
- Technical
- Relative Strength Index (RSI)
- DSP 53.27
- NMRA 52.19
- Support Level
- DSP $12.79
- NMRA $0.72
- Resistance Level
- DSP $13.72
- NMRA $0.85
- Average True Range (ATR)
- DSP 0.61
- NMRA 0.07
- MACD
- DSP 0.08
- NMRA -0.01
- Stochastic Oscillator
- DSP 95.48
- NMRA 62.35
About DSP Viant Technology Inc.
Viant Technology Inc is an advertising software company. The software enables the programmatic purchase of advertising, which is the electronification of the advertising buying process. It operates a cloud-based demand side platform ("DSP") that is used by marketers and its advertising agencies to centralize the planning, buying and measurement of its advertising across channels, including connected TV (CTV), streaming audio, digital out-of-home, mobile and desktop.
About NMRA Neumora Therapeutics Inc.
Neumora Therapeutics Inc is a clinical-stage biopharmaceutical company founded to confront the brain disease crisis by taking a fundamentally different approach to the way treatments for brain diseases are developed. It has scaled its therapeutic pipeline, which currently consists of seven clinical and preclinical neuroscience programs that target novel mechanisms of action for a broad range of underserved neuropsychiatric disorders and neurodegenerative diseases. Its pipeline includes NMRA-140, NMRA-511, NMRA-266, NMRA-M4R, NMRA-NMDA, NMRA-CK1O, NMRA-NLRP3, and NMRA-GCASE. The group's pipeline is building programs for underserved neuropsychiatric disorders and neurodegenerative diseases.